1. Home
  2. PRVA vs ARQT Comparison

PRVA vs ARQT Comparison

Compare PRVA & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Privia Health Group Inc.

PRVA

Privia Health Group Inc.

HOLD

Current Price

$21.12

Market Cap

3.0B

Sector

Technology

ML Signal

HOLD

Logo Arcutis Biotherapeutics Inc.

ARQT

Arcutis Biotherapeutics Inc.

HOLD

Current Price

$25.08

Market Cap

3.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRVA
ARQT
Founded
2007
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.0B
3.5B
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
PRVA
ARQT
Price
$21.12
$25.08
Analyst Decision
Buy
Strong Buy
Analyst Count
12
6
Target Price
$31.17
$34.00
AVG Volume (30 Days)
1.2M
1.6M
Earning Date
05-07-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
63.64
88.79
EPS
0.09
0.03
Revenue
$2,122,842,000.00
$376,072,000.00
Revenue This Year
$18.19
$34.85
Revenue Next Year
$10.72
$29.39
P/E Ratio
$235.56
$845.00
Revenue Growth
22.26
91.34
52 Week Low
$19.53
$15.10
52 Week High
$28.82
$31.77

Technical Indicators

Market Signals
Indicator
PRVA
ARQT
Relative Strength Index (RSI) 28.17 42.14
Support Level $19.90 $24.91
Resistance Level $24.65 $28.35
Average True Range (ATR) 0.79 1.30
MACD -0.10 -0.16
Stochastic Oscillator 30.46 12.10

Price Performance

Historical Comparison
PRVA
ARQT

About PRVA Privia Health Group Inc.

Privia Health Group Inc is one of the physician enablement companies in the United States with a presence in around 24 states and the District of Columbia. The group builds scaled provider networks with primary-care centric medical groups, risk-bearing entities, a physician-led governance structure, and the Privia Platform comprising an extensive suite of technology and service solutions. It collaborates with medical groups, health plans, and health systems to optimize approximately 1,300+ physician practices, improve the patient experience for over 5.8+ million patients, and reward around 5,300+ physicians and practitioners for delivering high-value care.

About ARQT Arcutis Biotherapeutics Inc.

Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.

Share on Social Networks: